IBIO iBio, Inc.
Price Chart
Executive Summary
iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line with expectations. The company highlighted regulatory clearance for IBIO-600 Phase 1 trial in Australia and preclinical data for IBIO-610, but operating losses widened to $8.4M from $4.9M a year ago. Cash runway extended into Q4 FY2028 via $17M warrant exercises, but the EPS miss and lack of revenue growth keep sentiment bearish.
Actionable Insight
The EPS miss and widening operating losses are negative signals for a pre-revenue biotech. However, the IBIO-600 Phase 1 start and $17M cash infusion provide near-term support. Watch for first participant dosing in Q2 2026 and any partnership news that could validate the pipeline. The stock's historical volatility (avg -10.78% T+20) suggests downside risk remains elevated.
Key Facts
- GAAP EPS -$0.07 vs consensus -$0.06 (miss of ~16.7%)
- Revenue $0 for Q3 FY2026, unchanged from prior year
- Operating loss widened to $8.4M from $4.9M YoY
- Cash and investments $74.8M as of March 31, 2026
- Received $17M from warrant exercises in Q4 FY2026, extending cash runway into Q4 FY2028
- Received regulatory clearance for IBIO-600 Phase 1 trial in Australia
- Preclinical data for IBIO-610 showed 6.7% visceral fat reduction in obese NHPs
- Expanded pipeline into PH-HFpEF with bispecific antibody program
Financial Impact
EPS miss of ~$0.01 vs consensus; operating loss increased by $3.5M YoY to $8.4M; cash runway extended by $17M warrant exercise
Risk Factors
- EPS miss of 16.7% vs consensus may pressure near-term sentiment
- Operating losses continue to widen with no near-term revenue catalyst
- Preclinical data for IBIO-610 is from a small, not statistically powered study
- Dilution risk from warrant exercises and potential future offerings
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293395 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
3
| $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $1.73 (+17.69%) |
|
May 12, 2026
28d ago
|
Press Release
| $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $1.73 (−11.61%) |
|
May 8, 2026
4w ago
|
8-K
| $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $1.73 (+4.22%) |
|
Apr 8, 2026
8w ago
|
8-K
| $2.24 $2.10 | ▼ −6.25% | ▼ −9.77% | $1.73 (−22.77%) |
|
Mar 19, 2026
11w ago
|
Insider Cluster
| $2.10 $1.74 | ▼ −17.14% | ▼ −14.93% | $1.73 (−17.62%) |
|
Mar 19, 2026
11w ago
|
Insider Cluster
| $2.10 $1.74 | ▼ −17.14% | ▼ −14.93% | $1.73 (−17.62%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $2.46 $2.08 | ▼ −15.45% | ▼ −12.79% | $1.73 (−29.67%) |
|
Mar 9, 2026
13w ago
|
EFFECT
| $2.50 $2.39 | ▼ −4.40% | ▼ −3.05% | $1.73 (−30.80%) |
|
Feb 27, 2026
14w ago
|
S-3
| $2.69 $2.50 | ▲ +7.06% | ▲ +5.86% | $1.73 (+35.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access